5-Alpha-Reductase Inhibitors and Combination Therapy

被引：19

作者：

Fuellhase, Claudius ^{[1
]}

Schneider, Marc P. ^{[2
]}

机构：

[1] Univ Rostock, Dept Urol, Ernst Heydemann Str 6, D-18057 Rostock, Germany

[2] Univ Zurich, Brain Res Inst, Swiss Fed Inst Technol Zurich, Dept Hlth Sci & Technol, Winterthurerstr 190, CH-8057 Zurich, Switzerland

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2016年 / 43卷 / 03期

关键词：

5-Alpha-reductase inhibitors; Finasteride; Dutasteride; Combination drug therapy; Prostatic hyperplasia; Lower urinary tract symptoms; BENIGN PROSTATIC HYPERPLASIA; URINARY-TRACT SYMPTOMS; DOUBLE-BLIND; FINASTERIDE THERAPY; TRANSURETHRAL RESECTION; ENLARGED PROSTATE; 5A-REDUCTASE INHIBITORS; CLINICAL PROGRESSION; SEXUAL FUNCTION; BLOOD-LOSS;

D O I：

10.1016/j.ucl.2016.04.003

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

By inhibiting the conversion from testosterone to dihydrotestosterone 5-Alpha reductase inhibitors (5ARIs) are able to hinder prostatic growth, shrink prostate volumes, and improve BPH-related LUTS. 5ARIs are particularly beneficial for patients with larger prostates (>30-40 mL). Generally the side effects of 5ARI treatment are mild, and according to the FORTA classification 5ARIs are suitable for frail elderly. 5ARI/alpha-blocker (AB) combination therapy showed the best symptomatic outcome and risk reduction for clinical progression. Combining Phosphodieseterase type 5 inhbibitors (PDE5Is) with 5ARIs counteracts the negative androgenic sexual side effects of 5ARIs, and simultaneously combines their synergistic effects on LUTS.

引用

页码：325 / +

页数：13

共 80 条

[1] The effect of 5α-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men
Amory, John K.
Anawalt, Bradley D.
Matsumoto, Alvin M.
Page, Stephanie T.
Bremner, William J.
Wang, Christina
Swerdloff, Ronald S.
Clark, Richard V.
[J]. JOURNAL OF UROLOGY, 2008, 179 (06) : 2333 - 2338
[2] CAN FINASTERIDE REVERSE THE PROGRESS OF BENIGN PROSTATIC HYPERPLASIA - A 2-YEAR PLACEBO-CONTROLLED STUDY
ANDERSEN, JT
EKMAN, P
WOLF, H
BEISLAND, HO
JOHANSSON, JE
KONTTURI, M
LEHTONEN, T
TVETER, K
BODKER, A
VEDEL, O
NORDLING, J
POULSEN, AL
SCHOU, J
HVIDT, V
HANSEN, JB
MEYHOFF, HH
ELDRUP, J
HARTWELL, D
COLSTRUP, H
LYNGDORF, P
NIELSEN, AH
LARSEN, E
WALTER, S
LARSEN, EH
THYBO, E
MOMMSEN, S
BROK, KE
PALM, L
GENSTER, H
ANDERSEN, M
KAUPPINEN, P
RAUVALA, M
HAKKINEN, J
TAMMELA, T
TAINIO, H
HYNNINEN, O
TIITINEN, J
LEHTORANTA, K
ALAOPAS, M
PERTTILA, I
PETAS, A
RINTALA, E
SALMINEN, R
JUUSELA, H
HANSSON, E
VONWENDT, R
TUHKANEN, K
TALJA, M
NURMI, M
PUNTALA, P
[J]. UROLOGY, 1995, 46 (05) : 631 - 637
[3] Effect of Dutasteride on the Risk of Prostate Cancer.
Andriole, Gerald L.
Bostwick, David G.
Brawley, Otis W.
Gomella, Leonard G.
Marberger, Michael
Montorsi, Francesco
Pettaway, Curtis A.
Tammela, Teuvo L.
Teloken, Claudio
Tindall, Donald J.
Somerville, Matthew C.
Wilson, Timothy H.
Fowler, Ivy L.
Rittmaster, Roger S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) : 1192 - 1202
[4] Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride
Andriole, GL
Marberger, M
Roehrborn, CG
[J]. JOURNAL OF UROLOGY, 2006, 175 (05) : 1657 - 1662
[5] Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial
Andriole, GL
Guess, HA
Epstein, JI
Wise, H
Kadmon, D
Crawford, ED
Hudson, P
Jackson, CL
Romas, NA
Patterson, L
Cook, TJ
Waldstreicher, J
[J]. UROLOGY, 1998, 52 (02) : 195 - 201
[6] The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases
Azzouni, Faris
Godoy, Alejandro
Li, Yun
Mohler, James
[J]. ADVANCES IN UROLOGY, 2012, 2012
[7] Finasteride for treatment of refractory hemospermia: prospective placebo-controlled study
Badawy, Abdelbasset A.
Abdelhafez, Alaa A.
Abuzeid, Abdelmoneim M.
[J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2012, 44 (02) : 371 - 375
[8] Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial
Borst, Stephen E.
Yarrow, Joshua F.
Conover, Christine F.
Nseyo, Unyime
Meuleman, John R.
Lipinska, Judyta A.
Braith, Randy W.
Beck, Darren T.
Martin, Jeffrey S.
Morrow, Matthew
Roessner, Shirley
Beggs, Luke A.
McCoy, Sean C.
Cannady, Darryl F., II
Shuster, Jonathan J.
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2014, 306 (04): : E433 - E442
[9] Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
Boyle, P
Gould, AL
Roehrborn, CG
[J]. UROLOGY, 1996, 48 (03) : 398 - 405
[10] Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates
Busetto, Gian Maria
Giovannone, Riccardo
Antonini, Gabriele
Rossi, Antonella
Del Giudice, Francesco
Tricarico, Stefano
Ragonesi, Giulia
Gentile, Vincenzo
De Berardinis, Ettore
[J]. BJU INTERNATIONAL, 2015, 116 (01) : 117 - 123

← 1 2 3 4 5 6 7 8 →